Generic Oral Controlled Release Product Development: Formulation and Process Considerations
This chapter contains sections titled: Introduction: Generic Drug Industry Dynamics Patents and Exclusivity Hurdles Faced by the Generic Industry Dosage form Design and Formulation Considerations Biopharmaceutical Considerations Regulatory Considerations for Generic CR Conclusions References
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buchkapitel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 335 |
|---|---|
| container_issue | |
| container_start_page | 321 |
| container_title | |
| container_volume | |
| creator | Ahmed, Salah U Naini, Venkatesh |
| description | This chapter contains sections titled:
Introduction: Generic Drug Industry Dynamics
Patents and Exclusivity Hurdles Faced by the Generic Industry
Dosage form Design and Formulation Considerations
Biopharmaceutical Considerations
Regulatory Considerations for Generic CR
Conclusions
References |
| doi_str_mv | 10.1002/9780470640487.ch19 |
| format | Book Chapter |
| fullrecord | <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_wiley_ebooks_10_1002_9780470640487_ch19_ch19</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EBC4031396_167_544</sourcerecordid><originalsourceid>FETCH-LOGICAL-p198f-688786424bbf8adfe05c7ca946b7a70308931a4b7d572812e5a23e3be44331503</originalsourceid><addsrcrecordid>eNpt0E1PwyAYwHGM0TjnvoCnfoFN3qHezHTTZInG6MkDofRpVsVSodPop7fdvGjkAAeeHyF_hE4JnhGM6VmuNOYKS465VjO3JvkeOiaEaCwxo3IfTX4mqGBEiUM0yqkSmCqtj9AkpWfcL95rJUboaQkNxNplt9H6bB6aLgbvoczuwYNNkN3FUG5cl13CO_jQvkLTnWeLEF833nZ1aDLblMOQg5QGn-oS4vYmnaCDyvoEk59zjB4XVw_z6-nqdnkzv1hNW5Lraiq1Vlpyyoui0rasAAunnM25LJRVmGGdM2J5oUqhqCYUhKUMWAGcM0YEZmM02737UXv4NFCE8JLMr0zmq27NkMq0ZdUD9g8g2Ax9_8AtGrZe8Z1qY3jbQOp20PVF-nZubdsOYjIcM8JyaYhURvRf_AYVAH2F</addsrcrecordid><sourcetype>Enrichment Source</sourcetype><iscdi>true</iscdi><recordtype>book_chapter</recordtype><pqid>EBC4031396_167_544</pqid></control><display><type>book_chapter</type><title>Generic Oral Controlled Release Product Development: Formulation and Process Considerations</title><source>eBooks on EBSCOhost</source><creator>Ahmed, Salah U ; Naini, Venkatesh</creator><contributor>Park, Kinam ; Wen, Hong</contributor><creatorcontrib>Ahmed, Salah U ; Naini, Venkatesh ; Park, Kinam ; Wen, Hong</creatorcontrib><description>This chapter contains sections titled:
Introduction: Generic Drug Industry Dynamics
Patents and Exclusivity Hurdles Faced by the Generic Industry
Dosage form Design and Formulation Considerations
Biopharmaceutical Considerations
Regulatory Considerations for Generic CR
Conclusions
References</description><identifier>ISBN: 9780470253175</identifier><identifier>ISBN: 0470253177</identifier><identifier>EISBN: 1118060326</identifier><identifier>EISBN: 9781118060322</identifier><identifier>EISBN: 9780470640487</identifier><identifier>EISBN: 0470640480</identifier><identifier>DOI: 10.1002/9780470640487.ch19</identifier><identifier>OCLC: 927502788</identifier><identifier>LCCallNum: RS201.C64O725 2010</identifier><language>eng</language><publisher>United States: Wiley</publisher><subject>CHEMISTRY ; drug substance properties, critical role in bioequivalent generic CR product design ; generic CR product probability ‐ bioequivalent to branded product and comparable in vitro drug release ; generic oral controlled release product development ‐ formulation and process considerations</subject><ispartof>Oral Controlled Release Formulation Design and Drug Delivery, 2011, p.321-335</ispartof><rights>Copyright © 2010 John Wiley & Sons, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttps://ebookcentral.proquest.com/covers/4031396-l.jpg</thumbnail><link.rule.ids>775,776,780,789,27904</link.rule.ids></links><search><contributor>Park, Kinam</contributor><contributor>Wen, Hong</contributor><creatorcontrib>Ahmed, Salah U</creatorcontrib><creatorcontrib>Naini, Venkatesh</creatorcontrib><title>Generic Oral Controlled Release Product Development: Formulation and Process Considerations</title><title>Oral Controlled Release Formulation Design and Drug Delivery</title><description>This chapter contains sections titled:
Introduction: Generic Drug Industry Dynamics
Patents and Exclusivity Hurdles Faced by the Generic Industry
Dosage form Design and Formulation Considerations
Biopharmaceutical Considerations
Regulatory Considerations for Generic CR
Conclusions
References</description><subject>CHEMISTRY</subject><subject>drug substance properties, critical role in bioequivalent generic CR product design</subject><subject>generic CR product probability ‐ bioequivalent to branded product and comparable in vitro drug release</subject><subject>generic oral controlled release product development ‐ formulation and process considerations</subject><isbn>9780470253175</isbn><isbn>0470253177</isbn><isbn>1118060326</isbn><isbn>9781118060322</isbn><isbn>9780470640487</isbn><isbn>0470640480</isbn><fulltext>true</fulltext><rsrctype>book_chapter</rsrctype><creationdate>2011</creationdate><recordtype>book_chapter</recordtype><recordid>eNpt0E1PwyAYwHGM0TjnvoCnfoFN3qHezHTTZInG6MkDofRpVsVSodPop7fdvGjkAAeeHyF_hE4JnhGM6VmuNOYKS465VjO3JvkeOiaEaCwxo3IfTX4mqGBEiUM0yqkSmCqtj9AkpWfcL95rJUboaQkNxNplt9H6bB6aLgbvoczuwYNNkN3FUG5cl13CO_jQvkLTnWeLEF833nZ1aDLblMOQg5QGn-oS4vYmnaCDyvoEk59zjB4XVw_z6-nqdnkzv1hNW5Lraiq1Vlpyyoui0rasAAunnM25LJRVmGGdM2J5oUqhqCYUhKUMWAGcM0YEZmM02737UXv4NFCE8JLMr0zmq27NkMq0ZdUD9g8g2Ax9_8AtGrZe8Z1qY3jbQOp20PVF-nZubdsOYjIcM8JyaYhURvRf_AYVAH2F</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Ahmed, Salah U</creator><creator>Naini, Venkatesh</creator><general>Wiley</general><general>John Wiley & Sons, Inc</general><scope>FFUUA</scope></search><sort><creationdate>2011</creationdate><title>Generic Oral Controlled Release Product Development: Formulation and Process Considerations</title><author>Ahmed, Salah U ; Naini, Venkatesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p198f-688786424bbf8adfe05c7ca946b7a70308931a4b7d572812e5a23e3be44331503</frbrgroupid><rsrctype>book_chapters</rsrctype><prefilter>book_chapters</prefilter><language>eng</language><creationdate>2011</creationdate><topic>CHEMISTRY</topic><topic>drug substance properties, critical role in bioequivalent generic CR product design</topic><topic>generic CR product probability ‐ bioequivalent to branded product and comparable in vitro drug release</topic><topic>generic oral controlled release product development ‐ formulation and process considerations</topic><toplevel>online_resources</toplevel><creatorcontrib>Ahmed, Salah U</creatorcontrib><creatorcontrib>Naini, Venkatesh</creatorcontrib><collection>ProQuest Ebook Central - Book Chapters - Demo use only</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmed, Salah U</au><au>Naini, Venkatesh</au><au>Park, Kinam</au><au>Wen, Hong</au><format>book</format><genre>bookitem</genre><ristype>CHAP</ristype><atitle>Generic Oral Controlled Release Product Development: Formulation and Process Considerations</atitle><btitle>Oral Controlled Release Formulation Design and Drug Delivery</btitle><date>2011</date><risdate>2011</risdate><spage>321</spage><epage>335</epage><pages>321-335</pages><isbn>9780470253175</isbn><isbn>0470253177</isbn><eisbn>1118060326</eisbn><eisbn>9781118060322</eisbn><eisbn>9780470640487</eisbn><eisbn>0470640480</eisbn><abstract>This chapter contains sections titled:
Introduction: Generic Drug Industry Dynamics
Patents and Exclusivity Hurdles Faced by the Generic Industry
Dosage form Design and Formulation Considerations
Biopharmaceutical Considerations
Regulatory Considerations for Generic CR
Conclusions
References</abstract><cop>United States</cop><pub>Wiley</pub><doi>10.1002/9780470640487.ch19</doi><oclcid>927502788</oclcid><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISBN: 9780470253175 |
| ispartof | Oral Controlled Release Formulation Design and Drug Delivery, 2011, p.321-335 |
| issn | |
| language | eng |
| recordid | cdi_wiley_ebooks_10_1002_9780470640487_ch19_ch19 |
| source | eBooks on EBSCOhost |
| subjects | CHEMISTRY drug substance properties, critical role in bioequivalent generic CR product design generic CR product probability ‐ bioequivalent to branded product and comparable in vitro drug release generic oral controlled release product development ‐ formulation and process considerations |
| title | Generic Oral Controlled Release Product Development: Formulation and Process Considerations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T01%3A45%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=bookitem&rft.atitle=Generic%20Oral%20Controlled%20Release%20Product%20Development:%20Formulation%20and%20Process%20Considerations&rft.btitle=Oral%20Controlled%20Release%20Formulation%20Design%20and%20Drug%20Delivery&rft.au=Ahmed,%20Salah%20U&rft.date=2011&rft.spage=321&rft.epage=335&rft.pages=321-335&rft.isbn=9780470253175&rft.isbn_list=0470253177&rft_id=info:doi/10.1002/9780470640487.ch19&rft_dat=%3Cproquest_wiley%3EEBC4031396_167_544%3C/proquest_wiley%3E%3Curl%3E%3C/url%3E&rft.eisbn=1118060326&rft.eisbn_list=9781118060322&rft.eisbn_list=9780470640487&rft.eisbn_list=0470640480&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=EBC4031396_167_544&rft_id=info:pmid/&rfr_iscdi=true |